NCT07874139 Prospective Study on Antimicrobial RESIstance in Chronic Pulmonary DiseasE
| NCT ID | NCT07874139 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Condition | Chronic Lung Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 683 participants |
| Start Date | 2025-03-31 |
| Primary Completion | 2029-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 683 participants in total. It began in 2025-03-31 with a primary completion date of 2029-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational, multicentric prospective study aims to understand the prevalence and burden of antimicrobial resistance (AMR) in people with chronic lung diseases (CLD) across the globe, understanding also geographical variability and the risk factors for acquiring AMR. The primary objective is to understand the prevalence and burden of AMR in CLD both at a local and gloval level. Secondary objectives include: 1) understanding susceptibilities models of high priority pathogens in people with CLD; 2) understanding geographic variability in the prevalence of AMR in CLD; 3) analysing risk factors for AMR in CLD Participants will be recruited
Eligibility Criteria
Inclusion Criteria: * Patients of all ages with any chronic lung disease who, for clinical practice, underwent testingof at least one respiratory biological sample (sputum culture; bronchoaspirate; bronchoalveolar lavage; nasal swab; throat swab) within the 12 months prior to the visit. * Patients attending an outpatient clinic or hospitalized during the study period Exclusion Criteria: * Patients who have not signed the informed consent form * Absence of data in the patient record
Contact & Investigator
Andrea Gramegna
PRINCIPAL INVESTIGATOR
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Frequently Asked Questions
Who can join the NCT07874139 clinical trial?
This trial is open to participants of all sexes, studying Chronic Lung Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07874139 currently recruiting?
Yes, NCT07874139 is actively recruiting participants. Contact the research team at andrea.gramegna@unimi.it for enrollment information.
Where is the NCT07874139 trial being conducted?
This trial is being conducted at Ann Arbor, United States, Tirana, Albania, Frankston, Australia, Antwerp, Belgium and 11 additional locations.
Who is sponsoring the NCT07874139 clinical trial?
NCT07874139 is sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. The principal investigator is Andrea Gramegna at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano. The trial plans to enroll 683 participants.